Clinical Investigation

MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer

Alexandra K. Walker, PhD,* Katalin Karaszi, MSc,* Helen Valentine, MRSC,† Victoria Y. Strauss, PhD,‡
Ananya Choudhury, MA, PhD, MRCP, FRCR,† Shaun McGill, BM, BCh,* Kaisheng Wen, MD,§ Michael D. Brown, PhD,¶ Vijay Ramani, MB, BS, MS, FRCS(Urol),‖
Selina Bhattarai, MD, FRCPath,§ Mark T.W. Teo, PhD, FRCR,** Lingjian Yang, PhD,† Kevin A. Myers, PhD,††
Nayneeta Deshmukh, MB, ChB, FRCPath,††† Helen Denley, MB, ChB, FRCPath,††† Lisa Browning, MB, BS, FRCPath,§§‖ Sharon B. Love, BSc,¶¶
Gopa Iyer, MD,¶¶ Noel W. Clarke, MB, BS, ChM, FRCS(Urol),§§¶
Emma Hall, PhD,## Robert Huddart, MA, MB, BS, PhD, MRCP, FRCR,***
Nicholas D. James, MBBS, PhD, FRCP, FRCR,§§§
Peter J. Hoskin, MD, FRCPath, FRCR,++++,+++ Catharine M.L. West, PhD,† and Anne E. Kiltie, MA, DM, DSc, MRCP, FRCR* 

*CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom;† Translational Radiobiology Group, Division of Cancer Sciences, Christie Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom. 

Reprint requests to: Anne E. Kiltie, MA, DM, DSc, MRCP, FRCR, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Dr, Oxford OX3 7DQ, United Kingdom. Tel: +44 01865 617352; E-mail: anne.kiltie@oncology.ox.ac.uk

Alexandra Walker and Katalin Karaszi contributed equally to this work.

Catharine West and Anne Kiltie contributed equally to this work.

Disclosures: S.B., L.B., A.C., E.H., R.H., N.J., A.E.K., V.S., and C.W. report grant funding from Cancer Research UK during the conduct of the study. A.C. is a Senior Editor of IJROBP and reports nonfinancial support from ASCO and ESTRO; personal fees and nonfinancial support from Bayer PLC; grants from Prostate Cancer UK, Medical Research Council UK, and National Institute for Health Research UK; grants, personal fees, and nonfinancial support from Elekta AB; and personal fees from ASTRO, outside the submitted work. E.H. reports grants from Merck Sharp & Dohrn, grants and nonfinancial support from AstraZeneca, grants from Janssen-Cilag, grants and nonfinancial support from Bayer, grants from Aventis Pharma Limited (Sanofi), and grants from Accuray Inc., outside the submitted work. R.H. reports grants and personal fees from MSD and Roche; personal fees from Bristol Myers Squibb and Janssen; and grants from Elekta, outside the submitted work. G.I. reports personal fees from Bayer Pharmaceuticals, outside the submitted work. This work was funded by CRUK Biomarkers and Imaging Discovery and Development grant (C15140/A13492). The BC2001 trial was supported by grants (C547/A2606, C547/A6845, C9764/A9904, and C1491/A9895) from Cancer Research UK. The work was also supported by CRUK grant C2094/A11365, CRUK grant C5529/A16895, CRUK grant C5255/A15935, an MRC studentship MR/K301256/1, CRUK funding to the Cancer Research Manchester Centre (C147/A18083, C147/A25254), the NIHR Manchester, NIHR Oxford (Molecular Diagnostics Theme/Multimodal Pathology Theme), and Royal Marsden/Institute of Cancer Research Biomedical Research Centres. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Supplementary material for this article can be found at https://doi.org/10.1016/j.ijrobp.2019.03.015.

Int J Radiat Oncol Biol Phys, Vol. 104, No. 4, pp. 809–818, 2019 0360-3016/© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.ijrobp.2019.03.015
Nonmetastatic muscle-invasive bladder cancer (MIBC) can be treated with curative intent by either cystectomy or bladder preservation techniques, including radiation therapy (RT) alone or with a radiosensitizing agent if tolerated\(^1,2\); neoadjuvant cisplatin-based chemotherapy is often used for suitable patients. These approaches have a 40% to 60% cause-specific survival (CSS) rate at 3 years.\(^3,4\) With no randomized data available, treatment is currently based on patient choice after discussion with a urologist, oncologist, and nurse specialist.\(^5\) To date there are no validated biomarkers to predict the likely patient benefit from either approach.\(^6\)

We previously showed using immunohistochemistry (IHC) on pretreatment transurethral resection of bladder tumor (TURBT) specimens that high levels of MRE11, a DNA-damage signaling protein, predicted outcome after radical RT for MIBC in 2 independent cohorts, but not after cystectomy.\(^7\) Our results were subsequently independently validated in a Danish/German study.\(^8\)

The aims of the present study were (1) to evaluate the ability to standardize the MRE11 IHC assay and its scoring...
methodology across multiple centers in the United Kingdom, thus developing it to appropriate standards for clinical use (final stage of biomarker discovery and assay development phase)9 and (2) to again validate its correlation with outcome in 2 of the largest and most important recent randomized trials of bladder preservation in MIBC (prospective analysis of retrospective tissue collections; first stage of biomarker qualification phase). Reporting Recommendations for Tumor Marker Prognostic Studies guidelines were followed.9

**Methods and Materials**

Ethical approval was obtained from the National Research Ethics services in Manchester (project 09/H1013/24 and 10_NOCL_O1), Oxford (09/H0606/5), and Birmingham (REC 00/8/75). All trial patients consented to use of their tissue and data for research.

**Study populations**

Patients in the UK multicenter randomized controlled trials BCON and BC2001 were given RT as 64 Gy in 32 fractions over 6.5 weeks or 55 Gy in 20 fractions over 20 weeks. BCON patients were randomized between RT alone or RT with carbogen and nicotinamide (132 whole mount and 116 tissue microarray [TMA] samples available).1 BC2001 (CRUK/01/004) patients were randomized to RT alone or RT with 5-fluorouracil and mitomycin C (317 samples; split into test [n = 154] and validation [n = 163] cohorts).2 One hundred samples were obtained from a cystectomy series in Manchester.10

**Materials**

Pretreatment formalin-fixed paraffin-embedded TURBT samples (Table E1; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015) were available for the trial and cystectomy cohorts. For BCON, whole formalin-fixed paraffin-embedded blocks and 1 mm core TMAs from invasive areas (constructed in Manchester in 2011) were used. Two in-house “BIDD” TMAs containing 0.6 mm diameter cores were created for assay development in Oxford (Material E1; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). Sections (4 μm thick) were cut and stored at 4°C before use, with IHC performed no later than 1 month after cutting. A consultant uropathologist outlined areas of urothelial carcinoma invading the lamina propria (T1) and/or muscularis propria (T2) on hematoxylin and eosin— or MRE11-stained sections. Tumors with divergent differentiation within the invasive component were regarded as invasive urothelial carcinoma.

**MRE11 immunohistochemistry**

After pilot work, a standardized operating procedure (SOP) was produced for MRE11 IHC using a Leica BOND-MAXautostainer (Leica Microsystems GmbH, Wetzlar, Germany) according to the manufacturer’s instructions in Oxford, Manchester, and Birmingham (see Materials E1; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). Slides were dewaxed in Bond Dewax solution (AR9222, Leica Microsystems) and rehydrated through graded ethanol and distilled water. Tissue sections were washed using Bond Wash solution (AR9590, Leica Microsystems). Endogenous peroxidases were blocked using peroxidase block solution for 5 minutes, followed by antigen retrieval at pH 6 using Epitope Retrieval 1 solution (AR9961, Leica Microsystems) for 20 minutes at 100°C. Slides were then incubated with mouse monoclonal anti-MRE11 antibody (1:3,000, Abcam plc, Cambridge, UK, ab214, 1 mg/ml) for 15 minutes at room temperature. Primary antibody binding to tissue sections was visualized using a biotin-free Bond polymer refine detection system (DS9800, Leica Microsystems). After postprimary amplification for 8 minutes and detection with polymer for 8 minutes using 3,3′-diaminobenzidine for 10 minutes, slides were counterstained with hematoxylin for 1 minute.

Six control slides were included in every 30-slide run. Negative control samples were stained using a mouse monoclonal immunoglobulin (Dako, Glostrup, Denmark, X0931, 100 mg/L) diluted to the same concentration as the MRE11 antibody; samples consisted of 2 patient samples from the cohort being stained and 1 slide from the BIDD TMA and a commercial sample. Positive controls consisted of sections from 3 of the commercial bladder tumor samples and a BIDD TMA section stained with the MRE11 antibody.

During the study, the automated IHC was improved by adding a 30 minute 10% bovine serum albumin (BSA) preprimary antibody protein blocking step, increasing the primary antibody dilution from 1:3000 in 1% BSA to 1:6000 in 10% BSA and reducing the primary antibody incubation time from 15 minutes to 8 minutes. After reoptimization, IHC was repeated on the BCON TMAs (final SOP in Material E1; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015).

In Leeds, BCON samples were stained using an Autostainer Link 48 instrument (Dako, Inc) and an EnVision FLEX+, Mouse, High pH kit (Dako, K8002). Slides were deparaffinized and pretreated in the automated Dako PT Link system using heated Envision Flex target high pH retrieval solution. Endogenous peroxidases were blocked using Flex Peroxidase Block for 5 minutes. Slides were incubated with mouse monoclonal anti-MRE11 antibody (1:3,000, Abcam plc, ab214, 1 mg/mL) for 30 minutes at room temperature. After applying labelled polymer Flex/horseradish peroxidase for 20 minutes, the staining was visualized using Flex DAB+ substrate chromogen for 2 × 5 minutes, and slides were counterstained with hematoxylin.
**MRE11 scoring**

Slides were scanned using an Aperio ScanScope CS scanner (Leica Microsystems) at 40× magnification and visualized by ImageScope Viewer. Scoring similar to that we have described elsewhere⁷ was undertaken after training, with guidance sought on IHC interpretation from a histopathologist for challenging cases (details in Material E1; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). Briefly, 6 to 10 images (containing at least 100 cells) were taken from random fields within the invasive areas. Surface papillary tumors and carcinoma in situ were not scored. Care was taken to avoid taking images from areas distorted or damaged by diathermy or crush artefact and from necrotic areas, reducing the potential of including cells with unreliable immunostaining. Tumor nuclear MRE11 staining intensity was graded as 0 to 3+ (Fig. E1a; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015) by 2 to 3 independent scorers within each center using a guide composed of 30 images. The modal intensity for each of the 6 to 10 images was determined and an overall modal intensity score assigned to each case. Comparison was then made of results from individual scorers, with differences highlighted and a consensus reached for each center. Percentage positivity was determined by either (initially) counting 100 cells

![Diagram of experiments undertaken](https://doi.org/10.1016/j.ijrobp.2019.03.015)

**Fig. 1.** Schematic of experiments undertaken. *Abbreviations:* BHAM = Birmingham, MAN = Manchester, OXF = Oxford.
per image using ImageJ software (Bethesda, MD) or using a second standardization scoring guide with 30 images to estimate the percentage positivity. The mean percentage of positive cells was multiplied by the modal intensity to give a semiquantitative H-score (0-300, Table E2; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015).

Statistical analysis

Analyses were conducted independently via STATA in each cohort, with a 25% cut off used to allow comparison with previous publications. Within each center, for a cohort, the intrarater agreement of MRE11 intensity scores was assessed using the weighted kappa statistic via STATA kappaetc packages. The reliability of the percentage of positive scores was studied using intraclass correlation coefficient (ICC). A higher value indicates a better agreement between scorers. Between centers, the reliability of MRE11 intensity and percentage positive scores were assessed by the kappa statistic and the ICC, respectively. Associations between MRE11 H-score (≤25th percentile and >25th percentile) and bladder CSS were analyzed using Kaplan-Meier graphs with log-rank tests. In the BCON TMA cohort, a subgroup analysis was conducted for RT patients only. Hazard ratios were generated for MRE11 H-score >25th percentile using Cox regression with adjustment for treatment, stage, grade, completion of RT, pretreatment hemoglobin level, and number of RT fractions.

Results

A schematic of the study design is presented in Figure 1.

Staining and scoring reliability

The MRE11 assay was developed in Oxford (see original standard operating procedure). Staining was highly reproducible between runs. A working dilution of 1:3000 was agreed by A.K., K.K., and K.M. A range card was created from the MIBC samples from Oxford to represent 0, 1+, 2+, and 3+ intensity scores for tumor nuclear MRE11 expression (Fig. E1; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). A 30-sample PowerPoint slide deck (Microsoft, Redmond, WA) was then developed for subsequent scoring by A.K., K.K., A.C., and M.T. (the latter 2 were experienced in manual scoring). Blinded scoring resulted in concordance among scores from 4 observers in 57% of the 30 cases (87% agreement for 3 scorers). After discussion, agreement was achieved for all samples.

Initially 40 BCON slides (parallel whole sections) were stained and scored in Manchester and Oxford, and 7 months later a further 132 slides were stained and scored. Staining was similar between centers and antibody aliquots (Table 1 and Fig. E2; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015) and across time (Fig. 2a). However, scores were higher in Oxford, with 87 of the 132 samples (66%) scored as 3+ versus 50 (38%) in Manchester (Table 2). The data equated to H-score 25th percentile cut-points of 175.8 for Manchester and 204.1 for Oxford; in the test and validation cohorts of Choudhury et al., these were 130 and 76, respectively.

We concluded that automated staining and improved imaging resulted in higher scores than the manual methods previously used. The 1+/2+ and 2+/3+ cut-point boundaries were then redefined and a revised 30-slide template produced. Rescoring reduced the number of 3+ scores to 42 of 132 (32%) for Oxford and 17 of 132 (13%) for Manchester (Table 2), with respective median H-scores reduced from 197 to 148 and 195 to 149 (Table E2; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015).

Before the data were linked with survival outcomes, a more formal assessment of standardization of scoring methods was undertaken. Twenty randomly selected Oxford images were scored by 2 or 3 Manchester observers (C.W., H.V., A.C.), with consensus reached and comparison made with Oxford scores; a similar procedure was performed for 20 randomly selected Manchester images scored

| Table 1 | Intra- and intercenter scoring agreement |
|---------|-----------------------------------------|
|         | Initial staining                        | New staining                           |
|         | Kappa (95% CI) on intensity              | ICC (95% CI) on % positive cells       | Kappa (95% CI) on intensity | ICC (95% CI) on % positive cells |
| BCON (n=132) |                                    |                                         |                                |                                |
| Intracenter: Oxford scorers | 0.63 (0.52-0.73) | NA*                                        | 0.59 (0.49-0.68) | 0.90 (0.88-0.93) |
| Intracenter: Manchester scorers | 0.75 (0.64-0.85) | NA*                                        | 0.95 (0.91-0.99) | 0.98 (0.98-0.99) |
| Intercenter: Oxford-Manchester | 0.32 (0.17-0.47) | 0.73 (0.64-0.82) | 0.55 (0.41-0.70) | 0.91 (0.88-0.94) |
| BC2001 |                                    |                                         |                                |                                |
| Testing (n=144) | 0.66 (0.58-0.74) | 0.95 (0.93-0.96) | NA                                | NA                                |
| Validation (n=145) | 0.72 (0.62-0.83) | NA*                                        | NA                                | NA                                |

Abbreviations: CI = confidence interval; ICC = intraclass correlation coefficient; NA = not applicable.

* % positive cells were scored by 1 scorer.

1 Not possible to calculate as there was very little variation in slides for 1 scorer.
by 3 Oxford observers (A.K., K.K., A.W.). Manchester scores tended to be lower than Oxford scores. Three of 20 Manchester and 3 of 20 Oxford cases were discordant, although consensus was reached in all but 1 of the latter (Table E3; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015).

One hundred fifty-four BC2001 test slides were stained and 144 scored in both Oxford and Birmingham. The

Fig. 2. Comparison of MRE11 staining between (a) initial (May) Oxford and subsequent (December) Oxford and Manchester staining of BCON samples; (b) Leeds, Oxford, and Manchester staining of BCON samples; (c) reoptimized staining (Oxford new) on BIDD tissue microarray compared to Leeds staining and original Oxford staining (Oxford old).
Birmingham observer scored 102 (66%) samples as 3+ compared with 44 (29%) in Oxford. In Oxford, a further 163 BC2001 validation slides were stained and imaged (by K.K.), and staining intensity and estimated positive percentage were scored in 145 slides independently by 2 observers (A.K. and K.K.) and consensus scores reached.

Associations with cancer-specific survival

Analyses carried out using data generated with the initial staining procedure in BCON samples showed no significant associations between MRE11 expression and CSS (Fig. E4a and E4b; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). Analysis of evaluable samples from 221 training and validation BC2001 patients by Oxford confirmed the lack of significant association between MRE11 expression and CSS (log rank test, $P = .97$; Fig. E4c, available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). Analysis of 99 patients in the cystectomy cohort showed a lack of significant association between MRE11 expression and CSS (log rank test, $P = .19$; Fig. E4d, available online at https://doi.org/10.1016/j.ijrobp.2019.03.015).

Refinement of the assay

A subset of BCON samples ($n = 48$) stained in the Leeds Pathology Department (Fig. 2b and 2c Fig. E3, available online at https://doi.org/10.1016/j.ijrobp.2019.03.015) showed reduced nonspecific background staining compared with samples stained in Oxford and Manchester (Table E4; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). Additionally, in 20 of these samples there was an increase in the variation of staining intensities between tumors. Therefore, at Oxford attempts were made to improve the automated IHC staining on the BOND instrument to replicate that on the Dako processor. This involved adding a preprimary antibody protein blocking step, increasing the primary antibody dilution to 1:6000, and reducing the primary antibody incubation time (see Methods and Materials for details; final SOP in Material E1, available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). After reoptimization, staining was repeated on 116 TMA samples from BCON (Table 3). The reoptimized staining protocol resulted in moderate to high agreement between scorers (Fig. 2c, Table 1).

In the 116 BCON TMA patients, there was no significant association between MRE11 expression and CSS when expression was scored in Oxford (log rank test, $P = .20$) but was not seen in scores from Manchester (Fig. 3c and 3d).

Discussion

This study aimed to develop the MRE11 IHC assay for prospective clinical use. It was hoped the work would

| Intensity | BCON original | BCON revised | BC2001 test cohort | BC2001 validation cohort |
|-----------|---------------|--------------|--------------------|--------------------------|
|           | Oxford        | Manchester   | Oxford             | Birmingham               | Oxford |
| 0         | 0             | 0            | 0                  | 0                        | 0     |
| 1+        | 4             | 18           | 11                 | 22                       | 19    |
| 2+        | 24            | 48           | 62                 | 77                       | 81    |
| 3+        | 87            | 50           | 42                 | 17                       | 44    |
| Not good  | 17            | 16           | 17                 | 16                       | 10    |
| Total     | 132           | 132          | 132                | 132                      | 154   |

BCON uses original scoring cut points of Oxford versus Manchester and revised scoring cut points of Oxford versus Manchester. The BC2001 test cohort is Oxford versus Birmingham (K.W.), and the BC2001 validation cohort is Oxford.

Table 3 Baseline characteristics of the 116 patients in the BCON tissue microarray dataset

| Characteristics | n (%) or median (range) |
|-----------------|-------------------------|
| Median age (range), y | 75.65 (51.5-90.5) |
| Sex             |                         |
| Male            | 101 (87.07)             |
| Female          | 15 (12.93)              |
| Tumor stage     |                         |
| T1              | 5 (4.31)                |
| T2              | 83 (71.55)              |
| T3              | 23 (19.83)              |
| T4a             | 5 (4.31)                |
| Tumor:stromal ratio |                 |
| High            | 109 (96.46)             |
| Low             | 4 (3.54)                |
| Growth margins  |                         |
| Broad           | 4 (3.54)                |
| Infiltrative    | 109 (96.46)             |
| Growth patterns |                         |
| Both            | 47 (41.59)              |
| Papillary       | 10 (8.85)               |
| Solid           | 56 (49.56)              |
| Necrosis        |                         |
| No              | 47 (41.59)              |
| Yes             | 66 (58.41)              |
underpin the development of a trial randomizing patients to conventional versus MRE11-guided patient choice and subsequent introduction of routine MRE11 testing in the National Health Service. IHC is an attractive platform for clinical use, as illustrated by human epidermal growth factor receptor 2 testing, but routine implementation requires rigorous validation of the staining and scoring methods to ensure consistency and reliability across institutions. Automated staining aids standardization and efficiency by improving fidelity and workflow.

We present the first attempt to validate MRE11 IHC staining across centers using good clinical laboratory practice standards. This was a large collaborative effort, and we provide a robust level of validation. The findings highlight the challenges associated with standardizing an MRE11 IHC test. Staining was qualitatively reproducible between centers, but scoring was not. Although histopathologists did not score the samples, they provided training, input on interpretation, and arbitration on challenging cases. Problems with interobserver scoring agreement were highlighted by the Ki67 Working Group, where scoring in 22 laboratories in 11 countries yielded ICC values ranging from 0.84 to 0.93. Our ICC values for density scores were similar, ranging from 0.90 to 0.98, but there were discrepancies in intensity scores despite efforts to improve agreement between laboratories. Potential reasons for the poor concordance include insufficient training, potential subjective bias, or technical factors such as differences in screen resolution.

Scores generated by a single scorer in Birmingham (using the scoring cards generated, but with less intensive training) were more discordant than those generated in Oxford and Manchester, reflecting the need for external quality assessment schemes. Although training can improve levels of concordance (eg, for EGFR staining) some stains are intrinsically more difficult to score than others, including MRE11. Another issue is time taken for scoring, with the Leeds Consultant Histopathologist taking 25 to 30 minutes per case (see Material E1; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015). Automated digital image analysis might remove human scoring bias and allow rapid scoring of multiple samples. We
attempted to score a subset of samples using automated digital analysis but found that when optimized to higher-intensity samples, the results for low-intensity samples were inaccurate, and vice versa. Therefore, we did not pursue this. The development of more sophisticated algorithms might resolve this problem.

We failed to validate the previous findings by ourselves and others. Although this could be due to lack of biological effect, we think it is more likely the result of methodological issues, including problems in standardizing the automated staining and poor scoring reproducibility across centers because of difficulties in standardizing intensity scoring. Others found similar difficulties when studying ERCC1 expression using an 8F1 antibody in a large sample set from 2 phase 3 trials of adjuvant cisplatin intensity scoring. Others found similar difficulties when studying ERCC1 expression using an 8F1 antibody in a large sample set from 2 phase 3 trials of adjuvant cisplatin in lung cancer. A change in the batch of antibody used large sample set from 2 phase 3 trials of adjuvant cisplatin might resolve this problem.

From a biological point of view, it appears paradoxical that high expression of a DNA damage signaling protein (MRE11) might be associated with better outcomes after a DNA damaging agent (ionizing radiation). However, we recently observed a truncated version of MRE11 in a bladder cancer cell line, which is still detected by the antibody used in this study, and we hypothesize that this might act in a dominant-negative fashion. This hypothesis is currently under investigation in a separate study.

With the reoptimized staining method, in light of sample depletion, we only obtained MRE11 data on 116 BCON patients, which provided only 82% power to detect a change in 3-year CSS between 43% and 70% between 2 MRE11 groups, as reported previously. A nonsignificant trend for a difference in CSS was seen in patients receiving RT alone, but only in the samples stained and scored in Oxford. Carbogen and nicotinamide are given to reduce hypoxia within tumors and, by increasing the biological effectiveness of RT, can modify the association between MRE11 and CSS. With small numbers of patients, the RT-alone subgroup analysis was underpowered.

Despite our failure to validate MRE11 as a prognostic marker in RT patients, we cannot reject a role for MRE11 as a biomarker in MIBC. Indeed, a meta-analysis of the BCON RT alone with data obtained from 44 patients receiving bladder chemoradiation from Memorial Sloan Kettering (see Materials E1 for methods and results, Fig. E5; available online at https://doi.org/10.1016/j.ijrobp.2019.03.015) yielded a pooled hazard ratio for MRE11 >25th percentile of 0.47 (95% confidence interval, 0.13-1.03). This hazard ratio is similar to those reported previously (0.42 and 0.64). Furthermore, recently the Radiation Therapy Oncology Group has taken an alternative approach to scoring MRE11 using an internal control of the nuclear:cytoplasmic ratio of MRE11 and the more standardizable automated quantitative analysis approach with promising results. Indeed, other DNA damage response genes have proved more tractable. For example, a recent microscopy-based nucleotide excision repair assay to profile ERCC2 helicase domain mutations established a role for ERCC2 mutations as a predictive biomarker in bladder cancer treated with cisplatin-based chemotherapy. ERCC2 mutational status has now been incorporated as a predictive biomarker in risk-adapted MIBC clinical trials.

Limitations of our study include the eventual reduced statistical power resulting from sample attrition and possibly use of TMAs. However, studies have identified concordance between IHC scoring of ≥0.6 mm TMAs and whole tissue sections, especially with multiple same-patient cores. It is therefore reasonable to assume comparable results between the BCON whole tissue sections and 1 mm TMAs used here. In our study, death from other causes was treated as censored in the analysis. We attempted to apply competing risk analyses that take into account death from other causes. However, these resulted in findings similar to the analyses presented, and only 4 of 44 people in the Memorial Sloan Kettering cohort died from other causes. Therefore, we chose not to formally present competing risk analyses.

Numerous studies have identified potential IHC-based biomarkers, but only a few have obtained United States Food and Drug Administration approval. Despite the reduced stability of RNA versus protein, it is easier to measure at low abundance and with greater sensitivity and specificity. Generation of a gene signature that reflects MRE11 protein expression might provide a more robust biomarker than IHC. Further exploration of a gene classifier would be worthwhile.

Conclusions

In this study, we were unable to validate MRE11 as a robust, reproducible, predictive biomarker for RT response in MIBC. A large analysis of prospectively acquired tissue is required using the refined staining methodology, along with further exploration of automated digital scoring methods. Alternatively, biomarkers based on other proteins or genomic data may be better placed for clinical use in the future.

References

1. Hoskin PJ, Rojas AM, Bentzen SM, et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28:4912-4918.
2. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366:1477-1488.
3. Kotwal S, Choudhary A, Johnston C, et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008;70:456-463.
4. Booth CM, Siemens DR, Li G, et al. Curative therapy for bladder cancer in routine clinical practice: A population-based outcomes study. Clin Oncol (R Coll Radiol) 2014;26:506-514.
5. National Institute for Health and Care Excellence. Bladder cancer: Diagnosis and management. Available at: https://www.nice.org.uk/guidance/ng2. Accessed April 15, 2019.

6. Forker LJ, Choudhury A, Kiltie AE. Biomarkers of tumour radiosensitivity and predicting benefit from radiotherapy. Clin Oncol (R Coll Radiol) 2015;27:561-569.

7. Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010;70:7017-7026.

8. Laurberg JR, Brems-Eskildsen AS, Nordentoft I, et al. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int 2012;110:E1228-E1236.

9. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer 2005;93:387-391.

10. Ramani VA, Maddineni SB, Grey BR, et al. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol 2010;57:1058-1063.

11. Abramoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int 2004;11:36-42.

12. Hallgren KA. Computing inter-rater reliability for observational data: An overview and tutorial. Tutor Quant Methods Psychol 2012;8:23-34.

13. Perez EA, Cortes J, Gonzalez-Angulo AM, et al. HER2 testing: Current status and future directions. Cancer Treat Rev 2014;40:276-284.

14. O’Hurley G, Sjöstedt E, Rahman A, et al. Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol 2014;8:783-798.

15. Howat WJ, Lewis A, Jones P, et al. Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Methods 2014;70:34-38.

16. Leung SCY, Nielsen TO, Zabaglo L, et al. Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration. NPJ Breast Cancer 2016;2:16014.

17. Rüschhoff J, Kerr KM, Grote HJ, et al. Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: Round robin test. Arch Pathol Lab Med 2013;137:1255-1261.

18. Smittenaar P, Walker AK, McGill S, et al. Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer. Br J Cancer 2018;119:220-229.

19. Khosravi P, Kazemi E, Imaičinskis M, et al. Deep convolutional neural networks enable discrimination of digital pathology images. EBioMedicine 2018;27:317-328.

20. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isof orm expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013:368:1101-1110.

21. Nicholson J, Jevons SJ, Groselj B, et al. E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer. Cancer Res 2017;77:3027-3039.

22. Hoskin PJ, Saunders MI, Phillips H, et al. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer 1997;76:260-263.

23. Laurence VM, Ward R, Dennis IF, et al. Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients. Br J Cancer 1995;72:198-205.

24. Magliocco AM, Moughan J, Simko J, et al. The impact of MRE11 in nuclear to cytoplasmic ratio on outcomes in muscle invasive bladder cancer an analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2017;35:343.

25. Li Q, Damish AW, Frazier Z, et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin Cancer Res 2019;25:977-988.

26. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: Progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008;26:5630-5637.

27. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol 2008;18:89-97.

28. Xi X, Li T, Huang Y, et al. RNA Biomarkers: Frontier of precision medicine for cancer. Noncoding RNA 2017;3:E9.